Applied BioMath (www.appliedbiomath.com) announces the kick-off of the 2015-2016 QSP-SB Industry & Academia Symposium series. This week, top pharma and biotech representatives will meet along with local faculty, students, and post docs, for the Fall QSP-SB Industry & Academia Symposium. This Symposium:
Is an opportunity for presenting, learning, and discussing quantitative systems pharmacology (QSP) and systems biology (SB) topics.
Aims to foster an active community of industry and academic participants interested in these topics, and create a forum for sharing our successes and challenges.
Is one of three that will be held during the 2015-2016 academic year, alternating between local campuses.
Dr. John Burke, Co-Founder, President, and CEO of Applied BioMath, realized that such an industry-academic collaboration and networking opportunity was lacking in the QSP and SB community. He had benefited from and enjoyed a similar type of event hosted by the Cell Decision Process (CDP) Center (http://www.cdpcenter.org) during his post-doc work at MIT and HMS. With strong academic enthusiasm from thought leaders such as Douglas Lauffenburger and Peter Sorger, Dr. Burke and Applied BioMath initiated the QSP-SB Industry & Academia symposium series, modeled closely after the CDP meetings, and held the inaugural symposium last spring. Overwhelming industry response is more than doubling this year's attendees.
"As a company with both CEO and CSO having done their post-doc and PhD at MITrespectively, and seeing how the CDP strengthened science and community, I am very excited by the potential of growing this community, to support each other, meet the future modelers, and hear from thought leaders in industry and academia." –John M. Burke, PhD, Co-Founder, President, and CEO of Applied BioMath
Each symposium is typically comprised of two presentations from pharma and biotech researchers, along with networking opportunities. The Fall QSP-SB Industry & Academia symposium will feature Anne Heatherington, PhD, Vice President, Head of Quantitative Clinical Sciences at a leading pharmaceutical company, and Kevin Dykstra, PhD, President/CEO of qPharmetra.